Supernus Pharmaceuticals (SUPN) just completed its all‑stock merger with Indivior Pharmaceuticals, creating Supernus, Inc., and simultaneously requested delisting of its legacy shares after multiple index removals connected to the transaction. Recent trading tells a mixed story for Supernus Pharmaceuticals. The share price closed at $41.92 after a 7 day share price return of 2.34%, yet the 90 day share price return declined 10.64% and the 1 year total shareholder return fell 26.46%. However,...
The company is merging with a peer.
Q3’26 Total Net Revenue of $356 Million, Up 13% YoYRecord Quarterly Total SUBLOCADE® Net Revenue of $267 Million in Q3'26, Up 22% YoY Record Quarterly Net Income of $137 Million and Record Non-GAAP Net Income of $161 Million in Q3'26Record Quarterly Adjusted EBITDA of $211 Million in Q3'26, Up 76% YoYNet Income Margin of 39%, up 2,500 basis points YoY, Adjusted EBITDA Margin of 59%, Up 2,100 Basis Points YoYOn Track to Close Merger with Supernus on November 2nd RICHMOND, Va., Oct. 29, 2026 (GLOB
Detailed price information for Indivior Pharmaceuticals Inc (INDV-Q) from The Globe and Mail including charting and trades.
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 25, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company developing novel small molecule allosteric modulators for neurological disorders, today announced that it has regained full global rights to all GABAB positive allosteric modulator (PAM) assets discovered under its research collaboration with Indivior UK Limited (“Indivior”). The return of the rights follows Indivior’s ra
Detailed price information for Indivior Pharmaceuticals Inc (INDV-Q) from The Globe and Mail including charting and trades.
Indivior Pharmaceuticals Inc. (INDV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Indivior Pharmaceuticals Inc. (INDV) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Detailed price information for Indivior Pharmaceuticals Inc (INDV-Q) from The Globe and Mail including charting and trades.
Indivior Pharmaceuticals (INDV) recently drew investor attention after a period of mixed share performance, with the stock down 9% over the past month but still higher year to date. This move has prompted fresh questions about valuation. See our latest analysis for Indivior Pharmaceuticals. At the current share price of $36.87, Indivior Pharmaceuticals has seen short term momentum fade, with a 1 month share price return that declined 8.85%, although the 1 year total shareholder return of...
Detailed price information for Alkermes Plc (ALKS-Q) from The Globe and Mail including charting and trades.
Indivior's Sublocade growth and cost cuts are lifting earnings and cash flow, but pipeline setbacks, legal risks and valuation add caution.
This is the newest page. Registered accounts read further back.